title: Current status of engineered T-cell therapy for synovial sarcoma.
abstract: Synovial sarcoma is a rare soft tissue sarcoma characterized by a t(X;18) translocation, which results in a SYT-SSX gene fusion. In the metastatic setting, chemotherapy has limited, durable efficacy prompting the necessity for new therapeutic modalities. One emerging new strategy involves T-cell-directed therapy such as tumor-infiltrating lymphocytes or the development of T cells that are genetically engineered to express a T-cell receptor against a cancer testis antigen. Of these approaches, engineered T cells that recognize NY-ESO-1 are the furthest along in development. Completed and on-going clinical trials have shown promise and there are efforts to continue to optimize the current approach.
authors.affiliation: New York University Langone Medical Center, NY 10016, USA.
authors.forename: Matthew
authors.initials: M
authors.lastname: Dallos
authors.affiliation: Memorial Sloan Kettering Cancer Center, NY 10065, USA.|Weill Cornell Medical College, NY 10065, USA.
authors.forename: William D
authors.initials: WD
authors.lastname: Tap
authors.affiliation: Memorial Sloan Kettering Cancer Center, NY 10065, USA.|Weill Cornell Medical College, NY 10065, USA.
authors.forename: Sandra P
authors.initials: SP
authors.lastname: D'Angelo
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology; D002887:Chromosomes, Human, Pair 18 / Q000235:genetics*; D002986:Clinical Trials as Topic; D058750:Epithelial-Mesenchymal Transition; D005260:Female; D050939:Gene Fusion; D005818:Genetic Engineering; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D016246:Lymphocytes, Tumor-Infiltrating / Q000502:physiology* / Q000637:transplantation; D008297:Male; D008565:Membrane Proteins / Q000276:immunology; D009363:Neoplasm Proteins / Q000235:genetics; D011518:Proto-Oncogene Proteins / Q000235:genetics; D011948:Receptors, Antigen, T-Cell / Q000235:genetics*; D011993:Recombinant Fusion Proteins / Q000235:genetics*; D012097:Repressor Proteins / Q000235:genetics; D013584:Sarcoma, Synovial / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000502:physiology* / Q000637:transplantation
chemical_list: D000951:Antigens, Neoplasm; C104948:CTAG1B protein, human; D008565:Membrane Proteins; D009363:Neoplasm Proteins; D011518:Proto-Oncogene Proteins; D011948:Receptors, Antigen, T-Cell; D011993:Recombinant Fusion Proteins; D012097:Repressor Proteins; C093961:SS18 protein, human; C093962:synovial sarcoma X breakpoint proteins
keywords: NY-ESO-1; adoptive T-cell therapy; chimeric antigen receptor; engineered T cell; synovial sarcoma; tumor-infiltrating lymphocytes